Prognostic value of morphology and hormone receptor status in breast cancer - a population-based study.
Allemani, C;
Sant, M;
Berrino, F;
Aareleid, T;
Chaplain, G;
Coebergh, JW;
Colonna, M;
Contiero, P;
Danzon, A;
Federico, M;
+9 more...Gafà, L;
Grosclaude, P;
Hédelin, G;
Macè-Lesech, J;
Garcia, CM;
Paci, E;
Raverdy, N;
Tretarre, B;
Williams, EMI;
(2004)
Prognostic value of morphology and hormone receptor status in breast cancer - a population-based study.
British journal of cancer, 91 (7).
pp. 1263-1268.
ISSN 0007-0920
DOI: https://doi.org/10.1038/sj.bjc.6602153
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
We analysed the 5-year relative survival among 4473 breast cancer cases diagnosed in 1990-1992 from cancer registries in Estonia, France, Italy, Spain, the Netherlands and the UK. Among eight categories based on ICD-O codes (infiltrating ductal carcinoma, lobular plus mixed carcinoma, comedocarcinoma, 'special types', medullary carcinoma, not otherwise specified (NOS) carcinoma, other carcinoma and cancer without microscopic confirmation), the 5-year relative survival ranged from 66% (95% CI 61-71) for NOS carcinoma to 95% (95% CI 90-100) for special types (tubular, apocrine, cribriform, papillary, mucinous and signet ring cell); 27% (95% CI 18-36) for cases without microscopic confirmation. Differences in 5-year relative survival by tumor morphology and hormone receptor status were modelled using a multiple regression approach based on generalised linear models. Morphology and hormone receptor status were confirmed as significant survival predictors in this population-based study, even after adjusting for age and stage at diagnosis.